Kewpie <2809>.
The revised financial estimates for November 2024 were announced. Revenue was upwardly revised from ¥480 billion to ¥486 billion, and operating profit was upwardly revised from ¥31 billion to ¥34 billion, exceeding the consensus estimate of around ¥32.5 billion. Sales growth in each segment for commercial, industrial, and overseas markets exceeded initial expectations, resulting in increased earnings. In addition, dividend estimates were revised, and the end-of-year dividend estimate was upwardly revised from ¥27 per share to ¥31, an increase of ¥4. (Annual dividend will increase from ¥50 to ¥54).
Advantest <6857>
Continuing the strong rebound trend, the target price of ¥7,456 reached on February 16 is within reach. In the weekly chart, the rebound from the support line of the 52-week line, which is trending upwards, has clearly broken through the 13-week and 26-week lines. As the 13-week line has turned upwards, the Golden Cross with the 26-week line is likely to be a concern in the future. In addition, if the high in February is updated, the target price, which replaces the price drop from the high in February to the low in April (¥4,952), is ¥9,960.